A pilot study of ranolazine in patients with intermittent claudication

A. Ma, W. T. Garland, W. B. Smith, S. Skettino, M. T. Navarro, A. Q. Chan, B. E. Anderson, John P. Cooke

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Aim. This pilot study provides preliminary information regarding safety and changes in exercise performance during treatment with ranolazine extended-release in patients with reproducible claudication during exercise treadmill testing (ETT). Methods. We enrolled 45 patients with documented peripheral arterial disease, reproducible claudication on ETY, and ankle-brachial indices <0.85 at rest that decreased by at least 0.15% or 20% immediately postexercise. Randomized patients received double-blind treatment with either ranolazine 1000 mg b.i.d. (n=22) or placebo (n=23) for 4 weeks. Results. Compared with baseline, peak walking time (PWT) increased (mean±SEM) by 53±34 s with ranolazine (P=0.13) and by 41±33 s with placebo (P=0.22). Pain-free walking time during ETT increased by 62±18 s with ranolazine (P=0.002) and 36±18 s with placebo (P=0.045). Supplemental analyses, excluding patients with baseline exercise duration (16 min and (12 min, showed additional improvement with ranolazine on PWT. Conclusions. Ranolazine was well tolerated and these data provide a rationale for proceeding with a definitive trial.

Original languageEnglish (US)
Pages (from-to)361-369
Number of pages9
JournalInternational Angiology
Issue number4
StatePublished - Dec 2006


  • Intermittent claudication
  • Peripheral arterial diseases
  • Ranexa™
  • Ranolazine

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'A pilot study of ranolazine in patients with intermittent claudication'. Together they form a unique fingerprint.

Cite this